The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

Blood

Volumn 97, Issue 5, 2001, Pages 1413-1421

  Smolich, Beverly D ^a   Yuen, Helene A ^b   West, Kristina A ^b   Giles, Francis J ^b   Albitar, Maher ^b   Cherrington, Julie M ^b  

^a SUGEN INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BLAST CELL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0035282940     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1413     Document Type: Article

References (27)

1. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells
2. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor
3. Hematopoietic receptors of class III receptor-type tyrosine kinases
4. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus
5. Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor
6. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene
7. Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias
8. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias
9. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
10. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
11. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy
12. Evidence of increased angiogenesis in patients with acute myeloid leukemia
13. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
14. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
15. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
16. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
17. Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product
18. FLT3 ligand inhibits apoptosis and promotes survival of myeloid leukemia cell lines
19. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase
20. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells
21. AML: Immunophenotypic heterogeneity and prognostic significance of c-kit expression
22. Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia
23. Anti-angiogenesis: New concept for therapy of solid tumors
24. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
25. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
26. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
27. Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis